Pharmacogenomics of Heart Failure: a Systematic Review

References

• Go AS , MozaffarianD , RogerVLet al. Heart disease and stroke statistics--2013 update: a report from the american heart association . Circulation127 ( 1 ), e6 – e245 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• McMurray JJ , AdamopoulosS , AnkerSDet al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC . Eur. Heart J.33 ( 14 ), 1787 – 1847 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Senni M , RedfieldMM . Heart failure with preserved systolic function. A different natural history?J. Am. Coll. Cardiol.38 ( 5 ), 1277 – 1282 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JessupM , BozkurtBet al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines . J. Am. Coll. Cardiol.62 ( 16 ), e147 – e239 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bhatia RS , TuJV , LeeDSet al. Outcome of heart failure with preserved ejection fraction in a population-based study . N. Engl. J. Med.355 ( 3 ), 260 – 269 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Owan TE , HodgeDO , HergesRM , JacobsenSJ , RogerVL , RedfieldMM . Trends in prevalence and outcome of heart failure with preserved ejection fraction . N. Engl. J. Med.355 ( 3 ), 251 – 259 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Pitt B , PfefferMA , AssmannSFet al. Spironolactone for heart failure with preserved ejection fraction . N. Engl. J. Med.370 ( 15 ), 1383 – 1392 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• McMurray JJ , AdamopoulosS , AnkerSDet al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC . Eur. J. Heart Fail.14 ( 8 ), 803 – 869 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Israili ZH , HallWD . Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology . Ann. Intern. Med.117 ( 3 ), 234 – 242 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ , LeeAF , MortonJJ , PringleSD , StruthersAD . How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?Heart82 ( 1 ), 57 – 61 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Chan SW , HuM , TomlinsonB . The pharmacogenetics of beta-adrenergic receptor antagonists in the treatment of hypertension and heart failure . Expert Opin. Drug Metab. Toxicol.8 ( 7 ), 767 – 790 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Talbert RL . Pharmacokinetics and pharmacodynamics of beta blockers in heart failure . Heart Fail. Rev.9 ( 2 ), 131 – 137 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Exner DV , DriesDL , DomanskiMJ , CohnJN . Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction . N. Engl. J. Med.344 ( 18 ), 1351 – 1357 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Carson P , ZiescheS , JohnsonG , CohnJN . Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-heart failure trial study group . J. Card. Fail.5 ( 3 ), 178 – 187 ( 1999 ).
   PubMedGoogle Scholar
• Cohn JN , JohnsonG , ZiescheSet al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure . N. Engl. J. Med.325 ( 5 ), 303 – 310 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Taylor AL , ZiescheS , YancyCet al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure . N. Engl. J. Med.351 ( 20 ), 2049 – 2057 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Pare G , KuboM , ByrdJBet al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema . Pharmacogenet. Genomics23 ( 9 ), 470 – 478 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mahmoudpour SH , LeusinkM , van der PuttenLet al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis . Pharmacogenomics14 ( 3 ), 249 – 260 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lee DS , PencinaMJ , BenjaminEJet al. Association of parental heart failure with risk of heart failure in offspring . N. Engl. J. Med.355 ( 2 ), 138 – 147 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Abdel-Qadir HM , LeeDS . The contribution of familial and heritable risks in heart failure . Curr. Opin. Cardiol.22 ( 3 ), 214 – 219 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Rice GI , JonesAL , GrantPJ , CarterAM , TurnerAJ , HooperNM . Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study . Hypertension48 ( 5 ), 914 – 920 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Evans WE , RellingMV . Moving towards individualized medicine with pharmacogenomics . Nature429 ( 6990 ), 464 – 468 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Mahesh Kumar KN , RamuP , RajanS , ShewadeDG , BalachanderJ , AdithanC . Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a south indian population . J. Cardiovasc. Pharmacol.52 ( 5 ), 459 – 466 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Andersson B , SylvenC . The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure . J. Am. Coll. Cardiol.28 ( 1 ), 162 – 167 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Cambien F , PoirierO , LecerfLet al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction . Nature359 ( 6396 ), 641 – 644 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Rigat B , HubertC , Alhenc-GelasF , CambienF , CorvolP , SoubrierF . An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels . J. Clin. Invest.86 ( 4 ), 1343 – 1346 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Samani NJ , ThompsonJR , O’TooleL , ChannerK , WoodsKL . A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction . Circulation94 ( 4 ), 708 – 712 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Swedberg K , KjekshusJ . Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian enalapril survival study (CONSENSUS) . Am. J. Cardiol.62 ( 2 ), A60 – A66 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Cappola TP , DornGW2nd . Clinical considerations of heritable factors in common heart failure . Circ. Cardiovasc. Genet.4 ( 6 ), 701 – 709 ( 2011 ).
   PubMedGoogle Scholar
• Cicoira M , ZanollaL , RossiAet al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype . J. Am. Coll. Cardiol.37 ( 7 ), 1808 – 1812 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Tang WH , VagelosRH , YeeYG , FowlerMB . Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure . Am. Heart J.148 ( 5 ), 889 – 894 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Nelveg-Kristensen KE , Busk MadsenM , Torp-PedersenCet al. Pharmacogenetic risk stratification in angiotensin-converting enzyme inhibitor-treated patients with congestive heart failure: a retrospective cohort study . PLoS ONE10 ( 12 ), e0144195 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Winkelmann BR , RussAP , NauckMet al. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease . Am. Heart J.137 ( 4 Pt 1 ), 698 – 705 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Johnson T , GauntTR , NewhouseSJet al. Blood pressure loci identified with a gene-centric array . Am. J. Hum. Genet.89 ( 6 ), 688 – 700 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Johnson AD , Newton-ChehC , ChasmanDIet al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals . Hypertension57 ( 5 ), 903 – 910 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Imen T , GrissaMH , BoubakerHet al. AGT M235t polymorphism and heart failure in a cohort of tunisian population: diagnostic and prognostic value . Int. J. Clin. Exp. Med.8 ( 9 ), 16346 – 16351 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Jiang Z , ZhaoW , YuF , XuG . Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension . Chin. Med. J. (Engl.)114 ( 12 ), 1249 – 1251 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Beitelshees AL , ZinehI . Renin–angiotensin–aldosterone system (RAAS) pharmacogenomics: implications in heart failure management . Heart Fail. Rev.15 ( 3 ), 209 – 217 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Mehta PK , GriendlingKK . Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system . Am. J. Physiol. Cell Physiol.292 ( 1 ), C82 – C97 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Baudin B . Polymorphism in angiotensin II receptor genes and hypertension . Exp. Physiol.90 ( 3 ), 277 – 282 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Kloosterman WP , PlasterkRH . The diverse functions of microRNAs in animal development and disease . Dev. Cell11 ( 4 ), 441 – 450 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Haas U , SczakielG , LauferSD . MicroRNA-mediated regulation of gene expression is affected by disease-associated SNPs within the 3′-UTR via altered RNA structure . RNA Biol.9 ( 6 ), 924 – 937 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sethupathy P , BorelC , GagnebinMet al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes . Am. J. Hum. Genet.81 ( 2 ), 405 – 413 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Tiret L , BonnardeauxA , PoirierOet al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction . Lancet344 ( 8927 ), 910 – 913 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Bonnardeaux A , DaviesE , JeunemaitreXet al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension . Hypertension24 ( 1 ), 63 – 69 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Zhang JA , LiJR , QiaoYJ . Association of AGTR1 gene A1166C polymorphism with the risk of heart failure: a meta-analysis . Genet. Mol. Res.14 ( 3 ), 9163 – 9170 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Swedberg K , EnerothP , KjekshusJ , WilhelmsenL . Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group . Circulation82 ( 5 ), 1730 – 1736 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Ramanathan G , ElumalaiR , PeriyasamyS , LakkakulaB . Role of renin-angiotensin-aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney disease . Iran. J. Kidney Dis.8 ( 4 ), 265 – 277 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Brand E , ChatelainN , MulateroPet al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension . Hypertension32 ( 2 ), 198 – 204 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• McNamara DM , TamSW , SabolinskiMLet al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT trial . J. Am. Coll. Cardiol.48 ( 6 ), 1277 – 1282 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Bassett MH , ZhangY , ClyneC , WhitePC , RaineyWE . Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1 . J. Mol. Endocrinol.28 ( 2 ), 125 – 135 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Chen JF , JingJ , TanH , SongMB , YuSY , HuangL . Lack of association of CYP11B2-344C/T polymorphism with essential hypertension: a meta-analysis . Int. J. Clin. Exp. Med.8 ( 6 ), 9162 – 9167 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Cuoco MA , PereiraAC , Mota GdeF , KriegerJE , MansurAJ . Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure . Arq. Bras. Cardiol.90 ( 4 ), 252 – 256 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Contini M , CompagninoE , CattadoriGet al. ACE-inhibition benefit on lung function in heart failure is modulated by ACE insertion/deletion polymorphism . Cardiovasc. Drugs Ther.30 ( 2 ), 159 – 168 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• O’Toole L , StewartM , PadfieldP , ChannerK . Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure . J. Cardiovasc. Pharmacol.32 ( 6 ), 988 – 994 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Tiago AD , BadenhorstD , SkudickyDet al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy . Cardiovasc. Res.54 ( 3 ), 584 – 589 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Mcamara DM , HolubkovR , JanoskoKet al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure . Circulation103 ( 12 ), 1644 – 1648 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• McNamara DM , HolubkovR , PostavaLet al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure . J. Am. Coll. Cardiol.44 ( 10 ), 2019 – 2026 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Wu CK , LuoJL , TsaiCTet al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure . Pharmacogenomics J.10 ( 1 ), 46 – 53 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• de Denus S , Zakrzewski-JakubiakM , DubeMPet al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan . Ann. Pharmacother.42 ( 7 ), 925 – 932 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Cicoira M , RossiA , BonapaceSet al. Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure . Am. J. Med.116 ( 10 ), 657 – 661 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Cavallari LH , GrooVL , VianaMA , DaiY , PatelSR , StamosTD . Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure . Pharmacotherapy30 ( 1 ), 1 – 9 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• de Denus S , RouleauJL , MannDLet al. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials . Pharmacogenomics J. doi:10.1038/tpj.2016.4 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Yang J , ZhaoY , HaoPet al. Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk . PLoS ONE8 ( 5 ), e63309 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ma R , LiX , SuGet al. Angiotensin-converting enzyme insertion/deletion gene polymorphisms associated with risk of atrial fibrillation: a meta-analysis of 23 case–control studies . J. Renin Angiotensin Aldosterone Syst.16 ( 4 ), 793 – 800 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kjekshus J , SwedbergK , SnapinnS . Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS trial group . Am. J. Cardiol.69 ( 1 ), 103 – 107 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Zhang Q , ChenY , LiuQ , ShanQ . Effects of renin-angiotensin-aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF: a meta-analysis of 13 randomized controlled trials . Herz41 ( 1 ), 76 – 86 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Miller JA , ThaiK , ScholeyJW . Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II . Kidney Int.56 ( 6 ), 2173 – 2180 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Redon J , Luque-OteroM , MartellN , ChavesFJ , POLPRI Investigators . Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients . Pharmacogenomics J.5 ( 1 ), 14 – 20 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Kurland L , MelhusH , KarlssonJet al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients . J. Hypertens.19 ( 10 ), 1783 – 1787 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Kurland L , MelhusH , KarlssonJet al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial . J. Hypertens.20 ( 4 ), 657 – 663 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Konoshita T . Genomic Disease Outcome Consortium Study I. Do genetic variants of the renin–angiotensin system predict blood pressure response to renin–angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the renin–angiotensin system . Curr. Hypertens. Rep.13 ( 5 ), 356 – 361 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Su X , LeeL , LiXet al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor . Circulation115 ( 6 ), 725 – 732 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Latini R , MassonS , AnandIet al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT . Eur. Heart J.25 ( 4 ), 292 – 299 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Parsa A , KaoWH , XieDet al. APOL1 risk variants, race, and progression of chronic kidney disease . N. Engl. J. Med.369 ( 23 ), 2183 – 2196 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hasegawa M , KusuharaH , AdachiM , SchuetzJD , TakeuchiK , SugiyamaY . Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide . J. Am. Soc. NepHol.18 ( 1 ), 37 – 45 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial . Lancet353 ( 9146 ), 9 – 13 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Packer M , BristowMR , CohnJNet al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group . N. Engl. J. Med.334 ( 21 ), 1349 – 1355 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Packer M , CoatsAJ , FowlerMBet al. Effect of carvedilol on survival in severe chronic heart failure . N. Engl. J. Med.344 ( 22 ), 1651 – 1658 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Van Campen LC , VisserFC , VisserCA . Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature . J. Cardiovasc. Pharmacol.32 ( Suppl. 1 ), S31 – S35 ( 1998 ).
   PubMedGoogle Scholar
• De Peuter OR , VerberneHJ , KokWEet al. Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure . J. Nucl. Med.54 ( 10 ), 1733 – 1739 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Metra M , GiubbiniR , NodariS , BoldiE , ModenaMG , Dei CasL . Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol . Circulation102 ( 5 ), 546 – 551 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure . N. Engl. J. Med.344 ( 22 ), 1659 – 1667 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline . NDA 200297/s-013 Coreg (carvedilol) prescribing information ( 2005 ). www.accessdata.fda.gov/drugsatfda_docs/label/2005/020297s013lbl .
   Google Scholar
• Leopold G . Balanced pharmacokinetics and metabolism of bisoprolol [Abstract] . J. Cardiovasc. Pharmacol.8 ( Suppl. 1 ), 1 , S16 – S20 ( 1986 ).
   PubMedGoogle Scholar
• Novartis Pharmaceuticals Corporation . Lopressor prescribing information ( 2015 ). www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/lopressor.pdf .
   Google Scholar
• Willette RN , AiyarN , YueTLet al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats . J. Pharmacol. Exp. Ther.289 ( 1 ), 48 – 53 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Andreka P , AiyarN , OlsonLCet al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium . Circulation105 ( 20 ), 2429 – 2434 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Evaluation of Survival Trial I . A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure . N. Engl. J. Med.344 ( 22 ), 1659 – 1667 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Johnson JA , TerraSG . Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics . Pharm. Res.19 ( 12 ), 1779 – 1787 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Mason DA , MooreJD , GreenSA , LiggettSB . A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor . J. Biol. Chem.274 ( 18 ), 12670 – 12674 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Rathz DA , BrownKM , KramerLA , LiggettSB . Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking . J. Cardiovasc. Pharmacol.39 ( 2 ), 155 – 160 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Levin MC , MarulloS , MuntanerO , AnderssonB , MagnussonY . The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation . J. Biol. Chem.277 ( 34 ), 30429 – 30435 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Minatoguchi S , ItoH , IshimuraKet al. Modulation of noradrenaline release though presynaptic alpha 2-adrenoceptors in congestive heart failure . Am. Heart J.130 ( 3 Pt 1 ), 516 – 521 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Kolek MJ , CarlquistJF , Thaneemit-ChenSet al. The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure . J. Card. Fail.11 ( 9 ), 677 – 683 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Liggett SB , Mialet-PerezJ , Thaneemit-ChenSet al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure . Proc. Natl Acad. Sci. USA103 ( 30 ), 11288 – 11293 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Taylor MR , SlavovD , HumpHeyKet al. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure . Pharmacogenet. Genomics19 ( 1 ), 35 – 43 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Bristow MR , MurphyGA , Krause-SteinraufHet al. An alpha2c-adrenergic receptor polymorphism alters the norepinepHine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure . Circ. Heart Fail.3 ( 1 ), 21 – 28 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• O’Connor CM , FiuzatM , CarsonPEet al. Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2c adrenergic receptor polymorphisms . PLoS ONE7 ( 10 ), e44324 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Aleong RG , SauerWH , SauerWHet al. Prevention of atrial fibrillation by bucindolol is dependent on the beta(1)389 Arg/Gly adrenergic receptor polymorphism . JACC Heart Fail.1 ( 4 ), 338 – 344 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Aleong RG , SauerWH , RobertsonAD , LiggettSB , BristowMR . Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure . Circ. Arrhythm. Electrophysiol.6 ( 1 ), 137 – 143 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kao DP , DavisG , AleongRet al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation . Eur. J. Heart Fail.15 ( 3 ), 324 – 333 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Liggett SB , WagonerLE , CraftLLet al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure . J. Clin. Invest.102 ( 8 ), 1534 – 1539 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Borjesson M , MagnussonY , HjalmarsonA , AnderssonB . A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure . Eur. Heart J.21 ( 22 ), 1853 – 1858 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Magnusson Y , LevinMC , EggertsenRet al. Ser49gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy . Clin. Pharmacol. Ther.78 ( 3 ), 221 – 231 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• White HL , De BoerRA , MaqboolAet al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study . Eur. J. Heart Fail.5 ( 4 ), 463 – 468 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• van der Meer P , De BoerRA , WhiteHLet al. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy . J. Card. Fail.11 ( 4 ), 279 – 284 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Batty JA , HallAS , WhiteHLet al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy . Clin. Pharmacol. Ther.95 ( 3 ), 321 – 330 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Biolo A , ClausellN , SantosKGet al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy . Am. J. Cardiol.102 ( 6 ), 726 – 732 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Liggett SB , CresciS , KellyRJet al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure . Nat. Med.14 ( 5 ), 510 – 517 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Littlejohn MD , PalmerBR , RichardsAMet al. Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment . Eur. J. Heart Fail.10 ( 1 ), 55 – 59 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Sehnert AJ , DanielsSE , ElashoffMet al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol . J. Am. Coll. Cardiol.52 ( 8 ), 644 – 651 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Cresci S , KellyRJ , CappolaTPet al. Clinical and genetic modifiers of long-term survival in heart failure . J. Am. Coll. Cardiol.54 ( 5 ), 432 – 444 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Petersen M , AndersenJT , HjelvangBRet al. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients . Br. J. Clin. Pharmacol.71 ( 4 ), 556 – 565 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Petersen M , AndersenJT , Jimenez-SolemEet al. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the echos trial . Pharmacogenet. Genomics22 ( 10 ), 709 – 715 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fiuzat M , NeelyML , StarrAZet al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-action DNA substudy . Eur. J. Heart Fail.15 ( 3 ), 258 – 266 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Okamoto H , HoriM , MatsuzakiMet al. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study . Int. J. Cardiol.164 ( 2 ), 238 – 244 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pereira SB , VellosoMW , ChermontSet al. Beta-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity . Mol. Med. Rep.7 ( 1 ), 259 – 265 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kang S , HongX , RuanCWet al. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure . J. Transl. Med.13 , 44 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Design of the Beta-blocker Evaluation Survival Trial (BEST) . The BEST Steering Committee . Am. J. Cardiol.75 ( 17 ), 1220 – 1223 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• ARCA Biopharma announces second quarter 2015 operating results and provides update on recent accomplishments ( 2015 ). www.arcabiopharma.com/arca-biopharma-announces-second-quarter-2015-operating-results-and-provides-update-on-recent-accomplishments/ .
   Google Scholar
• Bristow MR , Krause-SteinraufH , NuzzoRet al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial . Circulation110 ( 11 ), 1437 – 1442 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Cohn JN , PfefferMA , RouleauJet al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) . Eur. J. Heart Fail.5 ( 5 ), 659 – 667 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Miranda SM , MoscavitchSD , PereiraSBet al. Heart failure patients with B1-adrenoreceptor polymorphisms have augmented carvedilol response as detected by cardiac I123-MIBG scintigraphy . Int. J. Cardiol.177 ( 1 ), 111 – 113 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chen L , MeyersD , JavorskyGet al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol . Pharmacogenet. Genomics17 ( 11 ), 941 – 949 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Luo M , BiY , XuYX . Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban chinese patients with heart failure . Chin. Med. J. (Engl.)120 ( 19 ), 1720 – 1723 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mialet Perez J , RathzDA , PetrashevskayaNNet al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure . Nat. Med.9 ( 10 ), 1300 – 1305 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Terra SG , HamiltonKK , PaulyDFet al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy . Pharmacogenet. Genomics15 ( 4 ), 227 – 234 ( 2005 ).
   PubMedGoogle Scholar
• Lobmeyer MT , GongY , TerraSGet al. Synergistic polymorphisms of beta1 and alpha2c-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure . Pharmacogenet. Genomics17 ( 4 ), 277 – 282 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• De Groote P , HelbecqueN , LamblinNet al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure . Pharmacogenet. Genomics15 ( 3 ), 137 – 142 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hu H , JuiHY , HuFC , ChenYH , LaiLP , LeeCM . Predictors of therapeutic response to beta-blockers in patients with heart failure in taiwan . J. Formos. Med. Assoc.106 ( 8 ), 641 – 648 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Metra M , CovoloL , PezzaliNet al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure . Cardiovasc. Drugs Ther.24 ( 1 ), 49 – 60 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Nonen S , OkamotoH , FujioYet al. Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1d are associated with the response to beta-blockers in dilated cardiomyopathy . Pharmacogenomics J.8 ( 1 ), 78 – 84 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lee HY , ChungWJ , JeonHKet al. Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study . Korean J. Intern. Med.31 ( 2 ), 277 – 287 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lowes BD , GillEA , AbrahamWTet al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure . Am. J. Cardiol.83 ( 8 ), 1201 – 1205 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Rau T , DungenHD , EdelmannFet al. Impact of the beta1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients . Clin. Pharmacol. Ther.92 ( 1 ), 21 – 28 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Baudhuin LM , MillerWL , TrainLet al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure . Am. J. Cardiol.106 ( 3 ), 402 – 408 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Terra SG , PaulyDF , LeeCRet al. Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure . Clin. Pharmacol. Ther.77 ( 3 ), 127 – 137 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Bristow MR , GinsburgR , UmansVet al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure . Circ. Res.59 ( 3 ), 297 – 309 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Leineweber K , BroddeOE . Beta2-adrenoceptor polymorphisms: relation between in vitro and in vivo phenotypes . Life Sci.74 ( 23 ), 2803 – 2814 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Troncoso R , MoragaF , ChiongMet al. Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol . Basic Clin. Pharmacol. Toxicol.104 ( 5 ), 374 – 378 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kaye DM , SmirkB , WilliamsC , JenningsG , EslerM , HolstD . Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure . Pharmacogenetics13 ( 7 ), 379 – 382 ( 2003 ).
   PubMedGoogle Scholar
• Truijen J , De PeuterOR , KimYSet al. Beta2-adrenergic receptor genotype influences the effect of nonselective vs. selective beta-blockade on baroreflex function in chronic heart failure . Int. J. Cardiol.153 ( 2 ), 230 – 232 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Vardeny O , DetryMA , MoranJJ , JohnsonMR , SweitzerNK . The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker . J. Cardiovasc. Pharmacol.52 ( 6 ), 500 – 506 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Biolo A , SalvaroR , ClausellN , SilvelloD , SantosKG , RohdeLE . Impact of beta-2 Th164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients . Braz. J. Med. Biol. Res.43 ( 6 ), 565 – 571 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Leineweber K , TenderichG , WolfCet al. Is there a role of the Thr164Ile-beta(2)-adrenoceptor polymorphism for the outcome of chronic heart failure? Basic Res. Cardiol. 101 ( 6 ), 479 – 484 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Small KM , ForbesSL , RahmanFF , BridgesKM , LiggettSB . A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2c-adrenergic receptor confers impaired coupling to multiple effectors . J. Biol. Chem.275 ( 30 ), 23059 – 23064 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Small KM , WagonerLE , LevinAM , KardiaSL , LiggettSB . Synergistic polymorphisms of beta1- and alpha2c-adrenergic receptors and the risk of congestive heart failure . N. Engl. J. Med.347 ( 15 ), 1135 – 1142 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Fiuzat M , WojdylaD , KitzmanDet al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-action (heart failure: a controlled trial investigating outcomes of exercise training) trial . J. Am. Coll. Cardiol.60 ( 3 ), 208 – 215 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wilkinson GR . Drug metabolism and variability among patients in drug response . N. Engl. J. Med.352 ( 21 ), 2211 – 2221 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Shin J , JohnsonJA . Pharmacogenetics of beta-blockers . Pharmacotherapy27 ( 6 ), 874 – 887 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Takekuma Y , TakenakaT , KiyokawaMet al. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis . Biol. Pharm. Bull.30 ( 3 ), 537 – 542 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Zhou SF . Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I . Clin. Pharmacokinet.48 ( 11 ), 689 – 723 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Crews KR , GaedigkA , DunnenbergerHMet al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update . Clin. Pharmacol. Ther.95 ( 4 ), 376 – 382 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Samer CF , LorenziniKI , RollasonV , DaaliY , DesmeulesJA . Applications of CYP450 testing in the clinical setting . Mol. Diagn. Ther.17 ( 3 ), 165 – 184 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cascorbi I . Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication . Eur. J. Clin. Invest.33 ( Suppl. 2 ), 17 – 22 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Blake CM , KharaschED , SchwabM , NageleP . A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics . Clin. Pharmacol. Ther.94 ( 3 ), 394 – 399 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bijl MJ , VisserLE , Van SchaikRHet al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users . Clin. Pharmacol. Ther.85 ( 1 ), 45 – 50 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sharp CF , GardinerSJ , JensenBPet al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure . Pharmacogenomics J.9 ( 3 ), 175 – 184 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Saito M , KawanaJ , OhnoTet al. Population pharmacokinetics of r- and s-carvedilol in Japanese patients with chronic heart failure . Biol. Pharm. Bull.33 ( 8 ), 1378 – 1384 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Nikolic VN , JankovicSM , Velickovic-RadovanovicRet al. Population pharmacokinetics of carvedilol in patients with congestive heart failure . J. Pharm. Sci.102 ( 8 ), 2851 – 2858 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shihmanter R , NulmanI , GolandSet al. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure . J. Clin. Pharm. Ther.39 ( 4 ), 432 – 438 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Takekuma Y , TakenakaT , KiyokawaMet al. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol . J. Pharm. Pharm. Sci.9 ( 1 ), 101 – 112 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Horiuchi I , NozawaT , FujiiNet al. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure . Biol. Pharm. Bull.31 ( 5 ), 976 – 980 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Batenburg WW , Van EschJH , GarreldsIMet al. Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade . J. Hypertens.24 ( 7 ), 1355 – 1363 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• de Groote P , HelbecqueN , LamblinNet al. Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure . Eur. J. Heart Fail.6 ( 1 ), 17 – 21 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Carmeliet P , NgYS , NuyensDet al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 . Nat. Med.5 ( 5 ), 495 – 502 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Ho QT , KuoCJ . Vascular endothelial growth factor: biology and therapeutic applications . Int. J. Biochem. Cell Biol.39 ( 7–8 ), 1349 – 1357 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Schultz A , LavieL , HochbergIet al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation . Circulation100 ( 5 ), 547 – 552 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation Group . The effect of digoxin on mortality and morbidity in patients with heart failure . N. Engl. J. Med.336 ( 8 ), 525 – 533 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Wyse DG , WaldoAL , DimarcoJPet al. A comparison of rate control and rhythm control in patients with atrial fibrillation . N. Engl. J. Med.347 ( 23 ), 1825 – 1833 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Ziff OJ , LaneDA , SamraMet al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data . BMJ351 , h4451 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M , AdamsKFJr , ColucciWS . Digoxin in the management of cardiovascular disorders . Circulation109 ( 24 ), 2959 – 2964 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M , Van VeldhuisenDJ , ColucciWS . Contemporary use of digoxin in the management of cardiovascular disorders . Circulation113 ( 21 ), 2556 – 2564 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Williamson KM , THasherKA , FultonKBet al. Digoxin toxicity: an evaluation in current clinical practice . Arch. Intern. Med.158 ( 22 ), 2444 – 2449 ( 1998 ).
   PubMedGoogle Scholar
• Goldberger ZD , GoldbergerAL . Therapeutic ranges of serum digoxin concentrations in patients with heart failure . Am. J. Cardiol.109 ( 12 ), 1818 – 1821 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Morita N , YasumoriT , NakayamaK . Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities . Biochem. Pharmacol.65 ( 11 ), 1843 – 1852 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Schinkel AH , WagenaarE , MolCA , Van DeemterL . P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs . J. Clin. Invest.97 ( 11 ), 2517 – 2524 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Uematsu T , YamaokaM , DotoR , TanakaH , MatsuuraT , FurusawaK . Expression of ATP-binding cassette transporter in human salivary ducts . Arch. Oral Biol.48 ( 1 ), 87 – 90 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Ambudkar SV , DeyS , HycynaCA , RamachandraM , PastanI , GottesmanMM . Biochemical, cellular, and pharmacological aspects of the multidrug transporter . Annu. Rev. Pharmacol. Toxicol.39 , 361 – 398 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S , BurkO , von RichterOet al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo . Proc. Natl Acad. Sci. USA97 ( 7 ), 3473 – 3478 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Aarnoudse AJ , DielemanJP , VisserLEet al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration . Pharmacogenet. Genomics18 ( 4 ), 299 – 305 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Chowbay B , LiH , DavidM , CheungYB , LeeEJ . Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression . Br. J. Clin. Pharmacol.60 ( 2 ), 159 – 171 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Comets E , VerstuyftC , LavielleM , JaillonP , BecquemontL , MentreF . Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters . Eur. J. Clin. Pharmacol.63 ( 5 ), 437 – 449 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Leschziner GD , AndrewT , PirmohamedM , JohnsonMR . ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research . Pharmacogenomics J.7 ( 3 ), 154 – 179 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Tanabe M , IeiriI , NagataNet al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene . J. Pharmacol. Exp. Ther.297 ( 3 ), 1137 – 1143 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Hodges LM , MarkovaSM , ChinnLWet al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein) . Pharmacogenet. Genomics21 ( 3 ), 152 – 161 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• McBride BF , YangT , RodenDM . Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG . Pharmacogenomics J.9 ( 3 ), 194 – 201 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chang H , RhaSY , JeungHCet al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients . Ann. Oncol.20 ( 2 ), 272 – 277 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Green H , SoderkvistP , RosenbergP , HorvathG , PetersonC . MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy . Clin. Cancer Res.12 ( 3 Pt 1 ), 854 – 859 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Johne A , KopkeK , GerloffTet al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene . Clin. Pharmacol. Ther.72 ( 5 ), 584 – 594 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Verstuyft C , SchwabM , SchaeffelerEet al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms . Eur. J. Clin. Pharmacol.58 ( 12 ), 809 – 812 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Sakaeda T , NakamuraT , HorinouchiMet al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects . Pharm. Res.18 ( 10 ), 1400 – 1404 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Kurata Y , IeiriI , KimuraMet al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein . Clin. Pharmacol. Ther.72 ( 2 ), 209 – 219 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Becquemont L , VerstuyftC , KerbRet al. Effect of grapefruit juice on digoxin pharmacokinetics in humans . Clin. Pharmacol. Ther.70 ( 4 ), 311 – 316 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Gerloff T , SchaeferM , JohneAet al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males . Br. J. Clin. Pharmacol.54 ( 6 ), 610 – 616 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Horinouchi M , SakaedaT , NakamuraTet al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin . Pharm. Res.19 ( 10 ), 1581 – 1585 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Niemeijer MN , Van Den BergME , DeckersJWet al. ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population . Heart101 ( 24 ), 1973 – 1979 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kurzawski M , BartnickaL , FlorczakM , GornikW , DrozdzikM . Impact of ABCB1 (MDR1) gene polymorphism and p-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients . Pharmacol. Rep.59 ( 1 ), 107 – 111 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Didomenico RJ , BressAP , Na-ThalangKet al. Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure . Pharmacotherapy34 ( 11 ), 1121 – 1131 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bartnicka L , KurzawskiM , DrozdzikA , Plonska-GosciniakE , GornikW , DrozdzikM . Effect of ABCB1 (MDR1) 3435C >T and 2677G >A, T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients . Pharmacol. Rep.59 ( 3 ), 323 – 329 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Kojda G , KottenbergK . Regulation of basal myocardial function by NO . Cardiovasc. Res.41 ( 3 ), 514 – 523 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Heidari MM , KhatamiM , HadadzadehMet al. Polymorphisms in NOS3, MTHFR, APOB and TNF-alpha genes and risk of coronary atherosclerotic lesions in Iranian patients . Res. Cardiovasc. Med.5 ( 1 ), e29134 ( 2016 ).
   PubMedGoogle Scholar
• Veldman BA , SpieringW , DoevendansPAet al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide . J. Hypertens.20 ( 10 ), 2023 – 2027 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Schneider MP , ErdmannJ , DellesC , FleckE , Regitz-ZagrosekV , SchmiederRE . Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase . J. Hypertens.18 ( 12 ), 1767 – 1773 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• McNamara DM , HolubkovR , PostavaLet al. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure . Circulation107 ( 12 ), 1598 – 1602 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• McNamara DM , TamSW , SabolinskiMLet al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial . J. Card. Fail.15 ( 3 ), 191 – 198 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• McNamara DM , TaylorAL , TamSWet al. G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT . JACC Heart Fail.2 ( 6 ), 551 – 557 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rame JE , TamSW , McNamaraDet al. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy . Circ. Heart Fail.2 ( 6 ), 541 – 548 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Peng LM , ChenXP , SunJet al. Influence of Aldh2 Glu504Lys polymorphism on nitroglycerin response in chronic heart failure and involvement of calcitonin gene related peptide (CGRP) . Int. J. Clin. Pharmacol. Ther.50 ( 10 ), 701 – 711 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Siffert W , ForsterP , JockelKHet al. Worldwide ethnic distribution of the g protein Beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and black African individuals . J. Am. Soc. NepHol.10 ( 9 ), 1921 – 1930 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Rame JE , DraznerMH , PostWet al. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload . Hypertension49 ( 4 ), 857 – 864 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Siffert W , RosskopfD , SiffertGet al. Association of a human G-protein beta3 subunit variant with hypertension . Nat. Genet.18 ( 1 ), 45 – 48 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Meirhaeghe A , BautersC , HelbecqueNet al. The human G-protein beta3 subunit C825T polymorphism is associated with coronary artery vasoconstriction . Eur. Heart J.22 ( 10 ), 845 – 848 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Siffert W . G-protein beta3 subunit 825T allele and hypertension . Curr. Hypertens. Rep.5 ( 1 ), 47 – 53 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Shepherd AM , McNayJL , LuddenTM , LinMS , MusgraveGE . Plasma concentration and acetylator phenotype determine response to oral hydralazine . Hypertension3 ( 5 ), 580 – 585 ( 1981 ).
   PubMed Web of Science ®Google Scholar
• Spinasse LB , SantosAR , SuffysPN , MuxfeldtES , SallesGF . Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension . Pharmacogenomics15 ( 2 ), 169 – 178 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chen Z , ZhangJ , StamlerJS . Identification of the enzymatic mechanism of nitroglycerin bioactivation . Proc. Natl Acad. Sci. USA99 ( 12 ), 8306 – 8311 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Beretta M , GorrenAC , WenzlMVet al. Characterization of the east Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1 . J. Biol. Chem.285 ( 2 ), 943 – 952 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Green SA , TurkiJ , InnisM , LiggettSB . Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties . Biochemistry33 ( 32 ), 9414 – 9419 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Green SA , ColeG , JacintoM , InnisM , LiggettSB . A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor . J. Biol. Chem.268 ( 31 ), 23116 – 23121 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Park HJ , KimSK , KangWS , KimYJ , ChoAR , ParkJK . Potential involvement of NET polymorphism in serotonin/norepinepHine reuptake inhibitor response in panic disorder . Nord. J. Psychiatry70 ( 4 ), 314 – 317 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Chen G , ZhouX , PathakA , DornGW , KraniasEG . The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure . Cardiology112 ( 3 ), 224 – 231 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chen G , ZhouX , NicolaouPet al. A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation . FASEB J.22 ( 6 ), 1790 – 1796 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Park S , LuKT , LiuXet al. Allele-specific expression of angiotensinogen in human subcutaneous adipose tissue . Hypertension62 ( 1 ), 41 – 47 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Inoue I , NakajimaT , WilliamsCSet al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro . J. Clin. Invest.99 ( 7 ), 1786 – 1797 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Dickson ME , ZimmermanMB , RahmouniK , SigmundCD . The -20 and -217 promoter variants dominate differential angiotensinogen haplotype regulation in angiotensinogen-expressing cells . Hypertension49 ( 3 ), 631 – 639 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Arai K , NakagomiY , IketaniMet al. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism . Hum. Genet.112 ( 1 ), 91 – 97 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Shin HJ , KimJY , CheongHS , NaHS , ShinHD , ChungMW . Functional study of haplotypes in UGT1A1 promoter to find a novel genetic variant leading to reduced gene expression . Ther. Drug Monit.37 ( 3 ), 369 – 374 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bhasker CR , McKinnonW , StoneAet al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance . Pharmacogenetics10 ( 8 ), 679 – 685 ( 2000 ).
   PubMedGoogle Scholar
• Impraim C , WangG , YoshidaA . Structural mutation in a major human aldehyde dehydrogenase gene results in loss of enzyme activity . Am. J. Hum. Genet.34 ( 6 ), 837 – 841 ( 1982 ).
   PubMed Web of Science ®Google Scholar
• Hung CC , ChiouMH , TengYN , HsiehYW , HuangCL , LaneHY . Functional impact of ABCB1 variants on interactions between p-glycoprotein and methadone . PLoS ONE8 ( 3 ), e59419 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Frey UH , EisenhardtA , LummenGet al. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer . Cancer Epidemiol. Biomarkers Prev.14 ( 4 ), 871 – 877 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Rankinen T , ChurchT , RiceTet al. Effect of endothelin 1 genotype on blood pressure is dependent on physical activity or fitness levels . Hypertension50 ( 6 ), 1120 – 1125 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hingorani AD . Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French lecture 2000 . Atherosclerosis154 ( 3 ), 521 – 527 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Tesauro M , ThompsonWC , RoglianiP , QiL , ChaudharyPP , MossJ . Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298 . Proc. Natl Acad. Sci. USA97 ( 6 ), 2832 – 2835 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Dries DL , VictorRG , RameJEet al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension . Circulation112 ( 16 ), 2403 – 2410 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Wang W , LiaoX , FukudaKet al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity . Circ. Res.103 ( 5 ), 502 – 508 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Morisaki T , GrossM , MorisakiH , PongratzD , ZollnerN , HolmesEW . Molecular basis of amp deaminase deficiency in skeletal muscle . Proc. Natl Acad. Sci. USA89 ( 14 ), 6457 – 6461 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Giacopelli F , MarcianoR , PistorioAet al. Polymorphisms in the osteopontin promoter affect its transcriptional activity . Physiol. Genomics20 ( 1 ), 87 – 96 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Mega JL , StitzielNO , SmithJGet al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials . Lancet385 ( 9984 ), 2264 – 2271 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mega JL , WalkerJR , RuffCTet al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind engage AF-TIMI 48 trial . Lancet385 ( 9984 ), 2280 – 2287 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hou X , ShiJ , SunH . Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis . Eur. J. Clin. Pharmacol.70 ( 9 ), 1041 – 1047 ( 2014 ).
   PubMed Web of Science ®Google Scholar